1. Home
  2. TBPH vs KOP Comparison

TBPH vs KOP Comparison

Compare TBPH & KOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • KOP
  • Stock Information
  • Founded
  • TBPH 2013
  • KOP 1988
  • Country
  • TBPH United States
  • KOP United States
  • Employees
  • TBPH N/A
  • KOP N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • KOP Forest Products
  • Sector
  • TBPH Health Care
  • KOP Basic Materials
  • Exchange
  • TBPH Nasdaq
  • KOP Nasdaq
  • Market Cap
  • TBPH 699.0M
  • KOP 680.9M
  • IPO Year
  • TBPH N/A
  • KOP 2006
  • Fundamental
  • Price
  • TBPH $13.95
  • KOP $28.88
  • Analyst Decision
  • TBPH Strong Buy
  • KOP Strong Buy
  • Analyst Count
  • TBPH 3
  • KOP 2
  • Target Price
  • TBPH $21.33
  • KOP $52.50
  • AVG Volume (30 Days)
  • TBPH 602.7K
  • KOP 189.1K
  • Earning Date
  • TBPH 08-12-2025
  • KOP 08-08-2025
  • Dividend Yield
  • TBPH N/A
  • KOP 1.11%
  • EPS Growth
  • TBPH N/A
  • KOP N/A
  • EPS
  • TBPH 0.26
  • KOP 0.73
  • Revenue
  • TBPH $77,205,000.00
  • KOP $1,992,600,000.00
  • Revenue This Year
  • TBPH $78.36
  • KOP N/A
  • Revenue Next Year
  • TBPH N/A
  • KOP $1.74
  • P/E Ratio
  • TBPH $54.52
  • KOP $39.50
  • Revenue Growth
  • TBPH 24.49
  • KOP N/A
  • 52 Week Low
  • TBPH $7.88
  • KOP $22.99
  • 52 Week High
  • TBPH $14.55
  • KOP $39.83
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 71.41
  • KOP 42.38
  • Support Level
  • TBPH $13.66
  • KOP $27.24
  • Resistance Level
  • TBPH $14.55
  • KOP $28.98
  • Average True Range (ATR)
  • TBPH 0.46
  • KOP 0.87
  • MACD
  • TBPH -0.02
  • KOP -0.00
  • Stochastic Oscillator
  • TBPH 56.20
  • KOP 50.77

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About KOP Koppers Holdings Inc.

Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.

Share on Social Networks: